Robert L. Parkinson, Jr., is chairman of the board and chief executive officer of Baxter International Inc.
Prior to joining Baxter in April 2004, Mr. Parkinson was dean of Loyola University Chicago’s School of Business Administration and Graduate School of Business. Previously, he had a distinguished 25-year career at Abbott Laboratories, serving in a variety of domestic and international management and leadership positions.
Parkinson began his career in 1975 with American Hospital Supply Corporation. He joined Abbott in 1976 and held a number of marketing and management positions there before being named vice president of European operations in 1990, president of the Chemical and Agricultural division in 1993, and president of the International division responsible for pharmaceutical, hospital and nutritional products in 1995. In 1998, he became a member of its Board of Directors before being named president and chief operating officer of the company in 1999. He retired from Abbott in 2001.
He is active on a variety of industry boards and community organizations. Parkinson serves on the Board of Directors for Chicago-based Northwestern Medical Group, the physician group subsidiary of Chicago-based Northwestern Memorial HealthCare; as chairman of Loyola University of Chicago’s Board of Trustees; FIRST (For Inspiration and Recognition of Science and Technology); and Junior Achievement of Chicago; and is the past chairman of the Executives’ Club of Chicago.
Parkinson earned both a master’s degree in business administration and a bachelor’s degree from Loyola University Chicago.
Baxter International Inc. is an American health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company had 2013 sales of $15.3 billion, across two businesses: BioScience and Medical Products. Baxter’s BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine; and vaccines. Baxter’s Medical Products business produces intravenous solutions and other products used in the delivery of fluids and drugs to patients; inhalation anesthetics; contract manufacturing services; and products to treat end-stage renal disease, or irreversible kidney failure, including solutions and other products for peritoneal dialysis and hemodialysis.